Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Stromal Vascular Fraction (SVF) is an autologous, cell-based biologic therapy being investigated by the Midwestern Regional Medical Center for the treatment of chronic radiation-induced xerostomia in head and neck cancer patients. SVF is a heterogeneous mixture of cells—including adipose-derived stem cells (ADSCs), endothelial cells, pericytes, and pre-adipocytes—obtained from a patient's own adipose tissue via liposuction and processed using the Tissue Genesis Icellator cell isolation system. The therapy is administered via direct injection into the parotid and submandibular salivary glands. Its mechanism of action relies on the regenerative and paracrine properties of the constituent cells to repair damaged glandular tissue and restore saliva production, addressing the long-term side effects of radiotherapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stromal Vascular Fraction (City of Hope Chicago).